[go: up one dir, main page]

MX2015010320A - Metodos y dietas para proteger contra la quimiotoxicidad y enfermedades asociadas con la edad. - Google Patents

Metodos y dietas para proteger contra la quimiotoxicidad y enfermedades asociadas con la edad.

Info

Publication number
MX2015010320A
MX2015010320A MX2015010320A MX2015010320A MX2015010320A MX 2015010320 A MX2015010320 A MX 2015010320A MX 2015010320 A MX2015010320 A MX 2015010320A MX 2015010320 A MX2015010320 A MX 2015010320A MX 2015010320 A MX2015010320 A MX 2015010320A
Authority
MX
Mexico
Prior art keywords
subject
protein
age
levels
diseases associated
Prior art date
Application number
MX2015010320A
Other languages
English (en)
Other versions
MX382484B (es
Inventor
Valter D Longo
Sebastian Brandhorst
Morgan Elyse Levine
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of MX2015010320A publication Critical patent/MX2015010320A/es
Publication of MX382484B publication Critical patent/MX382484B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pediatric Medicine (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)

Abstract

Se proporciona un método para mejorar la longevidad y/o aliviar un síntoma de envejecimiento o prevenir las enfermedades asociadas con la edad. El método incluye un paso en el cual se determinan el promedio y tipo de ingesta de proteína diaria, IGF-1 y niveles de IGFBP1 y factores de riesgo para la mortalidad general, cáncer y diabetes del sujeto. Con respecto al consumo de proteína, se determinan las cantidades relativas de calorías de proteína de fuentes animales y vegetales. Una dieta calórica normal o baja en calorías periódica pero que imita al ayuno y baja en proteínas con frecuencias de cada 2 semanas hasta 2 meses se proporciona al sujeto si el nivel y tipo de ingesta de proteínas diario promedio del sujeto y/o los niveles de IGF-1 y/o niveles de IGFBP1 se identifican como más altos o más bajos que un nivel de corte de ingesta predeterminado y si el sujeto es más joven que una edad predeterminada. También se demuestra que el método alivia síntomas de quimiotoxicidad.
MX2015010320A 2013-02-12 2014-02-12 Una dieta para usarse en la reducción de niveles de glucosa y/o igf-1. MX382484B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361763797P 2013-02-12 2013-02-12
PCT/US2014/016025 WO2014127000A2 (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses

Publications (2)

Publication Number Publication Date
MX2015010320A true MX2015010320A (es) 2016-06-02
MX382484B MX382484B (es) 2025-03-13

Family

ID=51297596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010320A MX382484B (es) 2013-02-12 2014-02-12 Una dieta para usarse en la reducción de niveles de glucosa y/o igf-1.

Country Status (12)

Country Link
US (3) US9237761B2 (es)
EP (2) EP2956776A4 (es)
JP (2) JP6885671B2 (es)
KR (1) KR20150124962A (es)
CN (3) CN105008929B (es)
AU (3) AU2014216349B2 (es)
BR (1) BR112015019223A2 (es)
CA (1) CA2900782C (es)
ES (1) ES2807781T3 (es)
MX (1) MX382484B (es)
RU (2) RU2674681C2 (es)
WO (1) WO2014127000A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10015980B2 (en) 2012-10-22 2018-07-10 University Of Southern California Methods and formulations promoting tissue/organ regeneration, longevity and healthspan
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels
RU2672594C2 (ru) 2013-07-01 2018-11-16 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
KR20170003542A (ko) 2014-04-02 2017-01-09 유니버시티 오브 써던 캘리포니아 자가면역성 및 다발성 경화증 치료
WO2016130901A2 (en) 2015-02-12 2016-08-18 University Of Southern California Blockers of the growth hormone receptor in disease prevention and treatment
BR112017022244A2 (pt) * 2015-04-16 2018-07-10 Univ Southern California métodos para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia, método para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia ou outra terapia de câncer, método para substituir ou aprimorar um efeito de uma dieta que mimetiza jejum em sensibilização de célula cancerígena, e método
CN107872958A (zh) * 2015-05-06 2018-04-03 南加利福尼亚大学 治疗高血压和脂质紊乱的禁食模仿和加强膳食
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
BR112018014069A2 (pt) * 2016-01-12 2018-12-11 Univ Southern California uso de uma dieta de reforço e imitação de jejum, uso de uma dieta de reforço e imitação de jejum com um agente quimioterápico, e pacote de dieta.
AU2017219732B2 (en) 2016-02-15 2022-01-20 University Of Southern California Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
JP2019515009A (ja) * 2016-05-11 2019-06-06 ユニバーシティ オブ サザン カリフォルニア 自己免疫性／炎症性胃腸疾患の免疫制御性治療としての断食模倣食（ｆｍｄ）
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
US11504408B2 (en) * 2018-03-15 2022-11-22 University Of Southern California Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology
WO2019234628A1 (en) * 2018-06-07 2019-12-12 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
DE212018000421U1 (de) 2018-07-18 2021-03-01 Andreas Michalsen Auswirkungen einer kurzzeitigen Diät, die Fasten imitiert, auf die Lebensqualität und die Verträglichkeit einer Chemotherapie bei Patientinnen mit Krebs
US20200147112A1 (en) * 2018-10-04 2020-05-14 Meiji Co., Ltd. Diet therapy of intractable cancer and medical diet suitable therefor
EP3876741A4 (en) 2018-11-09 2022-08-31 L-Nutra NUTRIENT BAR FOR INTERMITTENT FASTING SIMULATE
JP2022530671A (ja) * 2019-04-30 2022-06-30 ユニバーシティ オブ サザン カリフォルニア アルツハイマー病（ａｄ）の介入のための断食模倣食（ｆｍｄ）
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
CN112273641A (zh) * 2019-07-23 2021-01-29 中国科学院上海营养与健康研究所 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法
WO2021126968A1 (en) * 2019-12-16 2021-06-24 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
US20230000888A1 (en) * 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
IT202000008740A1 (it) * 2020-04-23 2021-10-23 L Nutra Inc Composizione dietetica per l’incremento della massa magra e della massa muscolare
IT202000016957A1 (it) 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
US12029231B2 (en) * 2020-07-13 2024-07-09 L-Nutra Inc. Method for the treatment of depression
CA3192176C (en) * 2020-09-23 2025-05-06 Aminovita S.L. CANCER METABOLIC THERAPY
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
WO2024044036A1 (en) * 2022-08-23 2024-02-29 University Of Southern California Dietary compositions to extend longevity while maximizing strength and function
WO2025129163A1 (en) * 2023-12-14 2025-06-19 L-Nutra Inc. Longevity extending consumable products for maximizing strength and function, methods of consumption and manufacture

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406853B1 (en) * 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
US20030152947A1 (en) * 2001-06-15 2003-08-14 Crossman David C. Methods for detecting and treating the early onset of aging-related conditions
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050031671A1 (en) * 2003-08-06 2005-02-10 James Johnson Weight management, longevity and health paradigm
ATE498324T1 (de) * 2004-12-27 2011-03-15 Nestec Sa Verwendung von säuglingsnahrung mit reduziertem proteingehalt
AU2007211625B2 (en) * 2006-02-01 2012-08-23 Nestec S.A. Nutritional system and methods for increasing longevity
JP2011523626A (ja) * 2008-04-24 2011-08-18 ユニバーシティー オブ サウザン カリフォルニア，ユーエスシー スティーブンズ 化学療法、放射線療法、酸化ストレス、および加齢を防御するための食事組成物ならびに方法
CN101385543A (zh) * 2008-10-23 2009-03-18 上海交通大学 低蛋白食品及其制备方法
PL2490684T3 (pl) * 2009-10-22 2018-07-31 University Of Southern California Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu
US10015980B2 (en) * 2012-10-22 2018-07-10 University Of Southern California Methods and formulations promoting tissue/organ regeneration, longevity and healthspan
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels

Also Published As

Publication number Publication date
AU2022202764A1 (en) 2022-05-19
JP6885671B2 (ja) 2021-06-16
CN105008929B (zh) 2018-10-02
HK1212028A1 (en) 2016-06-03
US9237761B2 (en) 2016-01-19
CA2900782A1 (en) 2014-08-21
CN105008929A (zh) 2015-10-28
BR112015019223A2 (pt) 2017-07-18
US20170035094A1 (en) 2017-02-09
ES2807781T3 (es) 2021-02-24
EP3510875B1 (en) 2020-06-10
EP2956776A4 (en) 2016-12-21
CN109187991A (zh) 2019-01-11
AU2014216349A1 (en) 2015-08-06
RU2674681C2 (ru) 2018-12-12
EP3510875A1 (en) 2019-07-17
RU2015134780A (ru) 2017-03-20
KR20150124962A (ko) 2015-11-06
US20140227373A1 (en) 2014-08-14
JP2016509994A (ja) 2016-04-04
MX382484B (es) 2025-03-13
CN114236130A (zh) 2022-03-25
CN109187991B (zh) 2021-12-24
AU2020200297B2 (en) 2022-04-07
RU2018141475A3 (es) 2022-03-29
AU2020200297A1 (en) 2020-02-06
AU2014216349B2 (en) 2019-10-24
JP2020073473A (ja) 2020-05-14
RU2018141475A (ru) 2019-03-21
EP2956776A2 (en) 2015-12-23
WO2014127000A2 (en) 2014-08-21
CA2900782C (en) 2022-09-27
US20160331016A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
MX2015010320A (es) Metodos y dietas para proteger contra la quimiotoxicidad y enfermedades asociadas con la edad.
CY1123029T1 (el) Μετριασμος της βλαβης των ιστων και της ινωσης μεσω του αντισωματος anti-ltbp4
BR112012015753A2 (pt) composição nutricional com alto teor de proteína e baixa caloria para o estímulo de síntese de proteína muscular
DOP2015000231A (es) Sistemas y métodos para analizar alimentos para animales
MX393661B (es) Bolo para ternera.
ES2722973T3 (es) Obtención de imágenes en enfermedades neurológicas
RU2011144102A (ru) Снижение риска ожирения
Ayo et al. Heat stress, haematology and small intestinal morphology in broiler chickens: insight into impact and antioxidant-induced amelioration
MX376874B (es) Beta-caseina a2 y niveles de glucosa en sangre.
HN2008000906A (es) Enzimas para reducir el estres inmulogico
ES2673406T3 (es) Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes
AR098034A1 (es) Composición alimenticia para animales rumiantes que contiene carbohidratos y método de preparación
AR098035A1 (es) Composición alimenticia para animales rumiantes que contiene proteínas y método de preparación
MX2017014991A (es) Beta-caseina a2 y su capacidad antioxidante.
BR112017010431A2 (pt) método para aumentar os níveis de omega-3-s em carne
CL2017002931A1 (es) Método para incrementar la utilización de proteína de soja por peces salmónidos.
BR112015031428A2 (pt) novo uso da cantaxantina
Reddy et al. A study of the effect of vitamin C and Ocimum sanctum supplementation on antioxidant enzyme levels in broilers under heat-stress
BR112014016135A8 (pt) uso de uma fórmula para lactentes com caloria reduzida contendo nucleotídeos e/ou carotenóides para reduzir os efeitos adversos à saúde em uma idade mais avançada
Michalska et al. The Role of Micronutrient Supplementation in the Management of Hashimoto's Thyroiditis: A Review of Current Evidence and Potential Mechanisms of Action
MX2015005334A (es) Metodo de alimentacion de ganado para mejorar caracteristicas de canal.
BR112018010202A2 (pt) método para a criação de aves
Chen et al. Adolescent positive/negative thinking and mental health: The moderating roles of proactive coping and procrastination habit
Sahi et al. Oxidative stress in relation to obesity in Gujrati and non Gujarati young girls before and after maize diet.
Tesselaar et al. A study on certain factors that may affect the production and feed intake of breeding ostriches